Other · developed by Yarrow Bioscience
YB-101 is an experimental agent studied in Graves' disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07682896 | Phase 2 | Graves' Disease | Recruiting | YARW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Graves' Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the YARW page.
See YARW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
YARW catalysts and pipeline →